Results 1 to 10 of about 8,491 (183)

New-Onset Autoantibody-Negative Diabetes With DKA Following Lorlatinib Therapy for ALK-Positive NSCLC [PDF]

Case Reports in Endocrinology
Lorlatinib, a tyrosine kinase inhibitor used in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), is associated with adverse events, including hyperglycemia.
Ashni Dharia, Anna Pleet, Brittany West, Gayatri Jaiswal   +3 more
doaj   +3 more sources

Long-term efficacy and safety of lorlatinib versus alectinib in anaplastic lymphoma kinase-positive advanced/metastatic non-small cell lung cancer: matching-adjusted indirect comparison [PDF]

Journal of Comparative Effectiveness Research
Aim: Lorlatinib demonstrated superior efficacy over alectinib as a first-line treatment for ALK-positive (ALK+) advanced/metastatic non-small cell lung cancer in a matching-adjusted indirect comparison (MAIC) using 3-year follow-up data from CROWN ...
Todd Bauer, Devin Abrahami, Anna Polli, Haitao Chu, Priya Ramachandran, Conor Chandler, Min Tan, James Truscott, Julien Mazieres, Christine A Garcia   +9 more
doaj   +3 more sources

Olanzapine enabled rechallenge after lorlatinib‐induced psychosis: A case report [PDF]

PCN Reports
Background Lorlatinib is a third‐generation tyrosine kinase inhibitor for anaplastic lymphoma kinase (ALK)‐positive non‐small cell lung cancer (NSCLC).
Akiyoshi Yokode, Masaki Fujiwara, Yuko Nakamura, Kadoaki Ohashi, Shinji Sakamoto, Manabu Takaki   +5 more
doaj   +3 more sources

Efficacy and safety analysis of lorlatinib for ALK-positive advanced NSCLC: a multicentre real-world study in China [PDF]

BMC Cancer
Background Lorlatinib, a third-generation Anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitors (TKI), has demonstrated excellent curative effect in clinical studies to overcome mutations resistant to first- and second-generation ALK-TKIs.
Zhujun Chen, Chunlan Tang, Xiangyu Ma, Panwen Tian, Liang Gong   +4 more
doaj   +3 more sources

Cyp3a4-Mediated in vitro Metabolism and in vivo Disposition of Lorlatinib in Rats [PDF]

Drug Design, Development and Therapy
Cong Xie,1,2,* Tongshu Guan,1,2,* Jin Huang,1,2 Jiayu Chen,1,2 Yilei Li,1,2 Ping Zheng1,2 1Clinical Pharmacy Center, Nanfang Hospital, Southern Medical University, Guangzhou, People’s Republic of China; 2Department of Pharmacy, Nanfang ...
Xie C, Guan T, Huang J, Chen J, Li Y, Zheng P   +5 more
doaj   +3 more sources

Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results. [PDF]

Nature Medicine, 2023
Neuroblastomas harbor ALK aberrations clinically resistant to crizotinib yet sensitive pre-clinically to the third-generation ALK inhibitor lorlatinib.
Acharya, PT, Berko, ER, Chen, J, Chesler, L, Chi, Y-Y, Desai, AV, Ghazarian, S, Goldsmith, KC, Goodarzian, F, Granger, M, Groshen, SG, Kayser, K, Krytska, K, Lai, LM, Liyanage, M, Macy, ME, Malvar, J, Marachelian, A, Maris, JM, Marshall, L, Matthay, KK, Mody, R, Morgenstern, DA, Mossé, YP, Park, JR, Pawel, B, Peltz, G, Pinto, N, Schleiermacher, G, Shimada, H, Shusterman, S, States, L, Thurm, HC, Villablanca, JG, Vo, K   +34 more
core   +2 more sources

Kinetics and management of adverse events associated with lorlatinib after 5 years of follow-up in the CROWN study. [PDF]

Oncologist
Objective With 5 years of follow-up in the phase 3 CROWN study, lorlatinib showed unprecedented improvement in progression-free survival coupled with prolonged intracranial efficacy in patients with ALK-positive metastatic non-small cell lung cancer ...
Liu G, Solomon BJ, Mazieres J, Kim DW, Cortinovis D, Inoue T, Sharma R, Thurm H, Polli A, Bauer TM.   +9 more
europepmc   +2 more sources

Kinome Reprogramming of G2/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven Neuroblastoma. [PDF]

Mol Cancer Ther
Mutations in the tyrosine kinase domain of the anaplastic lymphoma kinase (ALK) oncogene in neuroblastoma occur most frequently at one of three hotspot amino acid residues, with the F1174* and F1245* variants conferring de novo resistance to first- and ...
Matkar S, East MP, Stuhlmiller TJ, Witek GM, Farrel A, Pastor S, Okumu DO, Kennedy A, Kalna JR, Berko ER, Casey CE, Krytska K, Patel K, Rokita JL, Gerelus M, Maris JM, Johnson GL, Mossé YP.   +17 more
europepmc   +2 more sources

Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study [PDF]

Journal of Clinical Oncology
ALK-positive; Non-small cell lung cancer; OutcomesALK positivo; Cáncer de pulmón de células no pequeñas; ResultadosALK positiu; Càncer de pulmó de cèl·lules no petites; ResultatsPurpose Lorlatinib improved progression-free survival (PFS) and ...
FELIP, ENRIQUETA, Liu, Geoffrey, MAZIERES, JULIEN, Mok, Tony, Solomon, Benjamin, Soo, Ross   +5 more
core   +2 more sources

Increased Cardiovascular Risk With Lorlatinib in Patients With ALK-Mutated Lung Cancer: A Real-World Comparative Study. [PDF]

J Am Heart Assoc
Background The discovery of driver mutations has transformed advanced non–small cell lung cancer treatment, with ALK (anaplastic lymphoma kinase)–rearranged patients achieving longest overall survival.
Lin CY, Su PL, Kuo CW, Tsai IL, Liu TH, Yang J, Lin CC, Lin SH.   +7 more
europepmc   +2 more sources